HCW Biologics Advances Solid Tumor Therapy with IND Application on Track for 2027

  • HCW Biologics is progressing toward filing an IND application for HCW11-018b, its lead T-Cell Engager candidate for solid tumors, with FDA guidance from a recent Type B meeting.
  • HCW11-018b combines a BiTE component with IL-15 and TGF-β trap domains to address immunosuppression in solid tumors.
  • Manufacturing of cGMP material for clinical trials is underway, with IND filing targeted for 1H 2027.
  • The candidate is part of HCW Biologics' second-generation T-Cell Engager Program using its proprietary TRBC platform technology.

HCW Biologics is addressing a critical gap in cancer immunotherapy: the limited effectiveness of T-Cell Engagers against solid tumors. By incorporating IL-15 and TGF-β trap domains, HCW11-018b aims to overcome immunosuppression in the tumor microenvironment, a key challenge in treating these difficult-to-treat cancers. The company's progress reflects broader industry efforts to develop next-generation immunotherapies that can penetrate and activate immune responses in solid tumors.

Regulatory Alignment
How the FDA's guidance will shape the IND application process and potential approval timeline for HCW11-018b.
Clinical Execution
Whether HCW Biologics can maintain its momentum and meet the 1H 2027 target for IND filing.
Therapeutic Differentiation
The pace at which HCW11-018b's multi-component design demonstrates superiority over existing BiTE therapies in solid tumors.